Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities.
暂无分享,去创建一个
Jeffrey M Peters | J. V. Vanden Heuvel | J. Peters | G. Perdew | Curtis J Omiecinski | Gary H Perdew | John P Vanden Heuvel | C. Omiecinski | J. Peters
[1] A. Y. Lu,et al. Immunochemical evidence for six forms of rat liver cytochrome P450 obtained using antibodies against purified rat liver cytochromes P450 and P448. , 1976, Molecular pharmacology.
[2] Jifeng Zhang,et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] T. Willson,et al. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. , 2006, Cancer research.
[4] P. Watkins,et al. Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.
[5] F. Gonzalez,et al. Ube2l3 gene expression is modulated by activation of the aryl hydrocarbon receptor: implications for p53 ubiquitination. , 2010, Biochemical pharmacology.
[6] K. Bock,et al. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. , 2009, Biochemical pharmacology.
[7] Ramalinga Kuruba,et al. A Functional Cross-Talk between Liver X Receptor-α and Constitutive Androstane Receptor Links Lipogenesis and Xenobiotic Responses , 2010, Molecular Pharmacology.
[8] K. Morimura,et al. Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.
[9] T. Willson,et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Fink,et al. Loss of the Aryl Hydrocarbon Receptor Induces Hypoxemia, Endothelin-1, and Systemic Hypertension at Modest Altitude , 2008, Hypertension.
[11] P. Demoly,et al. [Transgenic mice]. , 1992, Annales de dermatologie et de venereologie.
[12] M. Parker,et al. Structure and function of glutathione S-transferases. , 1994, Biochimica et biophysica acta.
[13] C. Glass,et al. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells , 2010, Nature Reviews Immunology.
[14] D. Moore,et al. Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. , 2004, Molecular endocrinology.
[15] W. Levin,et al. Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene. , 1967, Biochemical and biophysical research communications.
[16] R. Wortmann,et al. Myotoxicity associated with lipid-lowering drugs , 2007, Current opinion in rheumatology.
[17] Paul B Watkins,et al. Idiosyncratic Liver Injury: Challenges and Approaches , 2005, Toxicologic pathology.
[18] S. O’Rahilly,et al. PPAR gamma and human metabolic disease. , 2006, The Journal of clinical investigation.
[19] S. Kliewer,et al. The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. , 2004, Molecular cell.
[20] F. Gonzalez,et al. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.
[21] T. Brodie,et al. PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[22] C. Bradfield,et al. The Aryl Hydrocarbon Receptor sans Xenobiotics: Endogenous Function in Genetic Model Systems , 2007, Molecular Pharmacology.
[23] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[24] G. Perdew,et al. ERα-AHR-ARNT Protein-Protein Interactions Mediate Estradiol-dependent Transrepression of Dioxin-inducible Gene Transcription* , 2005, Journal of Biological Chemistry.
[25] S. Momohara,et al. Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. , 2008, The Journal of rheumatology.
[26] Y. Wan,et al. PPAR-gamma regulates osteoclastogenesis in mice. , 2007, Nature medicine.
[27] L. Pedersen,et al. Structure and function of sulfotransferases. , 2001, Archives of biochemistry and biophysics.
[28] L. Lovat,et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein , 2001, The Lancet.
[29] Vázquez Jj,et al. Liver-cell adenoma in an epileptic man on barbiturates , 1989 .
[30] R. Schears. Acute liver failure in the United States. , 2003, Annals of internal medicine.
[31] A. Akintobi,et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces matrix metalloproteinase (MMP) expression and invasion in A2058 melanoma cells. , 2006, Toxicology and applied pharmacology.
[32] David Y. Lai,et al. PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .
[33] J. Peters,et al. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[34] J. Ward,et al. Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α , 2004, Cancer Research.
[35] J. Lahtela,et al. Enzyme Inducers Improve Insulin Sensitivity in Non-insulin-dependent Diabetic Subjects , 1985, Diabetes.
[36] T. Willson,et al. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines , 2007 .
[37] A. Burdick,et al. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[38] S. Wakil,et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease , 2009, Proceedings of the National Academy of Sciences.
[39] H. Matsuo,et al. Peroxisome proliferators and retinoids affect JEG-3 choriocarcinoma cell function. , 1994, Endocrinology.
[40] L. Birnbaum,et al. Non-carcinogenic effects of TCDD in animals , 2000, Food additives and contaminants.
[41] W. Wahli,et al. Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA , 1997, The Journal of Biological Chemistry.
[42] S. Auerbach,et al. Di(2-ethylhexyl) phthalate Is a Highly Potent Agonist for the Human Constitutive Androstane Receptor Splice Variant CAR2 , 2009, Molecular Pharmacology.
[43] J. Miller,et al. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. , 1956, Cancer research.
[44] J. Kuroda,et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. , 2006, European journal of pharmacology.
[45] I. Issemann,et al. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.
[46] D. Moore,et al. Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. , 2005, Endocrinology.
[47] W. Wahli,et al. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. , 1998, Endocrinology.
[48] Jifeng Zhang,et al. Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor γ ligand , 2005 .
[49] T. Willson,et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity , 2003 .
[50] Jeffrey M Peters,et al. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. , 2009, Biochimica et biophysica acta.
[51] M. Negishi,et al. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. , 2008, Drug metabolism and pharmacokinetics.
[52] Margaret S. Wu,et al. Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects* , 1999, The Journal of Biological Chemistry.
[53] M. Q. Kemp,et al. Cyclooxygenase-2 Promoter Activation by the Aromatic Hydrocarbon Receptor in Breast Cancer MCF-7 Cells: Repressive Effects of Conjugated Linoleic Acid , 2007, Nutrition and cancer.
[54] T. Sueyoshi,et al. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. , 2001, Annual review of pharmacology and toxicology.
[55] G. Perdew,et al. Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. , 1999, Gene expression.
[56] A. Buchmann,et al. The effect of connexin32 null mutation on hepatocarcinogenesis in different mouse strains. , 1999, Carcinogenesis.
[57] W. Wahli,et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.
[58] M. Rao,et al. Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. , 1976, Cancer research.
[59] Christine Dreyer,et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.
[60] P. Meier,et al. Coordinate transcriptional regulation of transport and metabolism. , 2005, Methods in enzymology.
[61] Hongbing Wang,et al. Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin* , 2004, Journal of Biological Chemistry.
[62] J. Lehmann,et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.
[63] K. Scotto. Transcriptional regulation of ABC drug transporters , 2003, Oncogene.
[64] M. J. Coon,et al. Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes. , 1968, The Journal of biological chemistry.
[65] T. Fujiwara,et al. Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats , 1988, Diabetes.
[66] X. Chen,et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[67] C. Long,et al. PPAR-γ activation fails to provide myocardial protection in ischemia and reperfusion in pigs , 2005 .
[68] Jasmine Chen,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[69] Richard E. Peterson,et al. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. , 2009, Biochemical pharmacology.
[70] W. Xie,et al. Pregnane X Receptor and Constitutive Androstane Receptor at the Crossroads of Drug Metabolism and Energy Metabolism , 2010, Drug Metabolism and Disposition.
[71] W. Sabbagh,et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. , 1998, Genes & development.
[72] Peter J. Brown,et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .
[73] T. Misaka,et al. Dietary flavonoids activate the constitutive androstane receptor (CAR). , 2010, Journal of agricultural and food chemistry.
[74] T. Pineau,et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.
[75] L. Lasagna. Detoxication mechanisms. The metabolism and detoxication of drugs, toxic substances and other organic compounds , 1961 .
[76] A. Burdick,et al. The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. , 2006, Cellular signalling.
[77] A. Kong,et al. Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.
[78] X. Coumoul,et al. Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity , 2009, Oncogene.
[79] J. Buer,et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins , 2008, Nature.
[80] Wolfgang Meissner,et al. 15-Hydroxyeicosatetraenoic Acid Is a Preferential Peroxisome Proliferator-Activated Receptor β/δ Agonist , 2010, Molecular Pharmacology.
[81] Akane Kawamura,et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. , 2008, Toxicology.
[82] C. Fontaine,et al. Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes , 2004, Trends in Endocrinology & Metabolism.
[83] S. Strom,et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. , 2010, Biochemistry.
[84] J. Peters,et al. Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. , 2008, Biochemical and biophysical research communications.
[85] R. Hess,et al. NATURE OF THE HEPATOMEGALIC EFFECT PRODUCED BY ETHYL-CHLOROPHENOXY-ISOBUTYRATE IN THE RAT , 1965, Nature.
[86] Pierre Chambon,et al. The nuclear receptor superfamily: a personal retrospect on the first two decades. , 2005, Molecular endocrinology.
[87] W. J. Brammar,et al. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[88] T. Willson,et al. PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. , 2006, Cell death and differentiation.
[89] Michael Dean,et al. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. , 2005, Annual review of genomics and human genetics.
[90] M. Rao,et al. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. , 1993, The Journal of biological chemistry.
[91] K. Eder,et al. Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[92] M. Gallo,et al. Ah Receptor and NF-κB Interactions, a Potential Mechanism for Dioxin Toxicity* , 1999, The Journal of Biological Chemistry.
[93] R. Ye,et al. Cutting Edge: TLR2 Is a Functional Receptor for Acute-Phase Serum Amyloid A1 , 2008, The Journal of Immunology.
[94] M. Negishi,et al. Characterization of a Phenobarbital-responsive Enhancer Module in Mouse P450 Cyp2b10 Gene* , 1997, The Journal of Biological Chemistry.
[95] T. Willson,et al. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. , 2007, Carcinogenesis.
[96] W. Xie,et al. Receptor and Constitutive Androstane Receptor at the Crossroads of Drug Metabolism and Energy Metabolism , 2010 .
[97] S. Safe,et al. 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. , 1992, Toxicology and applied pharmacology.
[98] M. Konopleva,et al. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid and Related Compounds Inhibit Growth of Colon Cancer Cells through Peroxisome Proliferator-Activated Receptor γ-Dependent and -Independent Pathways , 2005, Molecular Pharmacology.
[99] M. Chojkier. Troglitazone and liver injury: In search of answers , 2005, Hepatology.
[100] M. Negishi,et al. Phenobarbital Confers its Diverse Effects by Activating the Orphan Nuclear Receptor Car , 2006, Drug metabolism reviews.
[101] Paul T Tarr,et al. Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.
[102] W. Fishman. Metabolic conjugation and metabolic hydrolysis , 1970 .
[103] L. Moore,et al. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. , 2003, Biochemistry.
[104] S. Strom,et al. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. , 2007, Toxicology and applied pharmacology.
[105] J. Miller,et al. The metabolism of methylated aminoazo dyes. VI. Intracellular distribution and properties of the demethylase system. , 1957, Cancer research.
[106] D. Moore,et al. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. , 2004, The Journal of clinical investigation.
[107] J. Peters,et al. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.
[108] J. V. Vanden Heuvel,et al. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[109] Wen Xie,et al. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. , 2006, Pharmacological reviews.
[110] Garet P Lahvis,et al. Resistance to 2,3,7,8-Tetrachlorodibenzo-p-dioxin Toxicity and Abnormal Liver Development in Mice Carrying a Mutation in the Nuclear Localization Sequence of the Aryl Hydrocarbon Receptor* , 2003, The Journal of Biological Chemistry.
[111] Johan Auwerx,et al. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[112] D. Moore,et al. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. , 2005, Molecular endocrinology.
[113] G. Perdew,et al. Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. , 2004, Molecular pharmacology.
[114] S. Amin,et al. Cellular and Pharmacological Selectivity of the Peroxisome Proliferator-Activated Receptor-β/δ Antagonist GSK3787 , 2010, Molecular Pharmacology.
[115] R. Evans,et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[116] E. Malle,et al. Serum amyloid A: An acute-phase protein involved in tumour pathogenesis , 2008, Cellular and Molecular Life Sciences.
[117] W. Wahli,et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.
[118] Raj Kumar,et al. The structure of the nuclear hormone receptors , 1999, Steroids.
[119] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[120] J. Lehmann,et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[121] J. Popp,et al. Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643. , 1994, Carcinogenesis.
[122] I. Jutooru,et al. 2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells. , 2007, Carcinogenesis.
[123] I. Issemann,et al. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.
[124] D. Moore,et al. The Xenobiotic Compound 1,4-Bis[2-(3,5-Dichloropyridyloxy)]Benzene Is an Agonist Ligand for the Nuclear Receptor CAR , 2000, Molecular and Cellular Biology.
[125] A. Billin,et al. PPARbeta/delta ligands as modulators of the inflammatory response. , 2008, Current opinion in investigational drugs.
[126] R. Ramsden,et al. Phenobarbital responsiveness conferred by the 5'-flanking region of the rat CYP2B2 gene in transgenic mice. , 1999, Gene.
[127] Wen Xie,et al. International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor α, Farnesoid X Receptor β, Liver X Receptor α, Liver X Receptor β, and Vitamin D Receptor , 2006, Pharmacological Reviews.
[128] B. Hagenbuch. Drug Uptake Systems in Liver and Kidney: A Historic Perspective , 2010, Clinical pharmacology and therapeutics.
[129] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[130] L. Perera,et al. Dephosphorylation of Threonine 38 Is Required for Nuclear Translocation and Activation of Human Xenobiotic Receptor CAR (NR1I3)* , 2009, The Journal of Biological Chemistry.
[131] Masayuki Yamamoto,et al. Effects of Aryl Hydrocarbon Receptor Signaling on the Modulation of Th1/Th2 Balance1 , 2005, The Journal of Immunology.
[132] C. Wolf,et al. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. , 2008, The Journal of clinical investigation.
[133] C. Falany,et al. Regulation of Human Hepatic Hydroxysteroid Sulfotransferase Gene Expression by the Peroxisome Proliferator-Activated Receptor α Transcription Factor , 2005, Molecular Pharmacology.
[134] J. Heuvel. Diet, fatty acids, and regulation of genes important for heart disease , 2004 .
[135] C. Waller,et al. Three-dimensional quantitative structure-activity relationships of dioxins and dioxin-like compounds: model validation and Ah receptor characterization. , 1995, Chemical research in toxicology.
[136] J. Auwerx,et al. The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.
[137] W. Wahli,et al. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. , 2002, Molecular cell.
[138] R. Evans,et al. Interactions between Hepatic Mrp4 and Sult2a as Revealed by the Constitutive Androstane Receptor and Mrp4 Knockout Mice* , 2004, Journal of Biological Chemistry.
[139] C. Handschin,et al. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. , 2005, Archives of biochemistry and biophysics.
[140] S. Amin,et al. Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity , 2010, Molecular Pharmacology.
[141] A. Burdick,et al. The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. , 2006, Cellular signalling.
[142] C. Wolf,et al. Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[143] T. Willson,et al. PPARβ/δ selectively induces differentiation and inhibits cell proliferation , 2006, Cell Death and Differentiation.
[144] S. Amin,et al. Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists. , 2008, Chemical research in toxicology.
[145] W. Wahli,et al. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression , 2006, Proceedings of the National Academy of Sciences.
[146] S Kettle,et al. Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis , 1994, Human & experimental toxicology.
[147] G. Perdew,et al. Ligand Selectivity and Gene Regulation by the Human Aryl Hydrocarbon Receptor in Transgenic Mice , 2009, Molecular Pharmacology.
[148] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[149] S. Lien,et al. Identification of a Novel Peroxisome Proliferator-Activated Receptor (PPAR) γ Promoter in Man and Transactivation by the Nuclear Receptor RORα1 , 2001 .
[150] Laura Bonati,et al. Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. , 2005, Archives of biochemistry and biophysics.
[151] Y. Yano,et al. Peroxisome proliferator‐activated receptor δ as a molecular target to regulate lung cancer cell growth , 2005 .
[152] J. Auwerx,et al. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. , 1998, FEBS letters.
[153] Wen Xie,et al. PXR and CAR in energy metabolism , 2009, Trends in Endocrinology & Metabolism.
[154] Jiandie D. Lin,et al. Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α , 2005, Cell.
[155] S. Safe,et al. Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. , 1996, Biochemical pharmacology.
[156] K. Willecke,et al. Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice. , 2000, Cancer research.
[157] M. Negishi,et al. CAR and PXR: The xenobiotic-sensing receptors , 2007, Steroids.
[158] J. Ward,et al. Peroxisome proliferator‐activated receptor‐β/δ protects against chemically induced liver toxicity in mice , 2007 .
[159] G. Perdew,et al. Ah receptor represses acute phase response gene expression without binding to its cognate response element , 2009, Laboratory Investigation.
[160] D. Nelson. The Cytochrome P450 Homepage , 2009, Human Genomics.
[161] G. Perdew,et al. The aryl hydrocarbon receptor complex and the control of gene expression. , 2008, Critical reviews in eukaryotic gene expression.
[162] M. Veldhoen,et al. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells , 2009, The Journal of experimental medicine.
[163] J. Reddy,et al. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. , 1983, Critical reviews in toxicology.
[164] Oliver Burk,et al. Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor , 2005, Molecular Pharmacology.
[165] L. Moore,et al. Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes* , 2003, The Journal of Biological Chemistry.
[166] J. Auwerx,et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[167] H. Isomäki,et al. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. , 1993, The Journal of rheumatology.
[168] B. Staels,et al. Peroxisome Proliferator-activated Receptor α Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme* , 2003, Journal of Biological Chemistry.
[169] S. Auerbach,et al. Alternatively spliced isoforms of the human constitutive androstane receptor. , 2003, Nucleic acids research.
[170] Ying Zheng,et al. PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[171] D. Moore,et al. Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR , 2002, Science.
[172] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.
[173] R. Evans,et al. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.
[174] L. Moore,et al. Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.
[175] Hongbing Wang,et al. Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.
[176] Y. Wan,et al. PPAR-γ regulates osteoclastogenesis in mice , 2007, Nature Medicine.
[177] S. Duensing,et al. A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention , 2010, Molecular Cancer.
[178] Y. Fujii‐Kuriyama,et al. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells , 2008, Proceedings of the National Academy of Sciences.
[179] S. Auerbach,et al. Retinoid X Receptor-α-Dependent Transactivation by a Naturally Occurring Structural Variant of Human Constitutive Androstane Receptor (NR1I3) , 2005, Molecular Pharmacology.
[180] D. Waxman,et al. Synthetic Drugs and Natural Products as Modulators of Constitutive Androstane Receptor (Car) and Pregnane X Receptor (PXR) , 2006, Drug metabolism reviews.
[181] H. Remmer. Die Beschleunigung der Evipanoxydation und der Demethylierung von Methylaminoantipyrin durch Barbiturate , 2004, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.
[182] G. Prendergast,et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.
[183] C. Glass,et al. The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.
[184] T. Omura,et al. A new cytochrome in liver microsomes. , 1962, The Journal of biological chemistry.
[185] Reena Rao,et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.
[186] D. Schrenk,et al. Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. , 2006, Molecular nutrition & food research.
[187] Béatrice Desvergne,et al. Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.
[188] G. Ailhaud,et al. Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes , 1995, The Journal of Biological Chemistry.
[189] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[190] S. Kliewer,et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.
[191] M E Hurtt,et al. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[192] K. Kawajiri,et al. Zinc finger transcription factor Slug is a novel target gene of aryl hydrocarbon receptor. , 2006, Experimental cell research.
[193] J. Ward,et al. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. , 2006, Carcinogenesis.
[194] P. Neuvonen,et al. Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients , 2002, European Journal of Clinical Pharmacology.
[195] M. Negishi,et al. CAR, driving into the future. , 2004, Molecular endocrinology.
[196] A. Hevener,et al. PPARdelta regulates glucose metabolism and insulin sensitivity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[197] D. Moore,et al. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements , 1994, Molecular and cellular biology.
[198] Josephine C. Adams,et al. Fascin-1 Promoter Activity Is Regulated by CREB and the Aryl Hydrocarbon Receptor in Human Carcinoma Cells , 2009, PloS one.
[199] Vicki L Dellarco,et al. Mode of action in relevance of rodent liver tumors to human cancer risk. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[200] M. Denison,et al. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. , 2003, Annual review of pharmacology and toxicology.
[201] B. Rigas,et al. Regulation of peroxisome proliferator‐activated receptor‐β/δ by the APC/β‐CATENIN pathway and nonsteroidal antiinflammatory drugs , 2009, Molecular carcinogenesis.
[202] A. Ferko,et al. [Pigmented hepatocellular adenoma of the liver caused by long-term use of phenobarbital]. , 2003, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti.
[203] T. Imazawa,et al. Promoting effect of peroxisome proliferators in two-stage rat renal tumorigenesis. , 1988, Cancer letters.
[204] T. Willson,et al. The Nuclear Receptor CAR Is a Regulator of Thyroid Hormone Metabolism during Caloric Restriction* , 2004, Journal of Biological Chemistry.
[205] S. Mulero-Navarro,et al. The dioxin receptor regulates the constitutive expression of the vav3 proto-oncogene and modulates cell shape and adhesion. , 2009, Molecular biology of the cell.
[206] Y Fujii-Kuriyama,et al. Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. , 1994, The Journal of biological chemistry.
[207] T. Willson,et al. Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. , 2007, Cellular signalling.
[208] T. Boyer. Special article the glutathione S‐transferases: An update , 1989 .
[209] Masayuki Yamamoto,et al. Intrinsic Function of the Aryl Hydrocarbon (Dioxin) Receptor as a Key Factor in Female Reproduction , 2005, Molecular and Cellular Biology.
[210] C. Long,et al. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. , 2005, American journal of physiology. Heart and circulatory physiology.
[211] M. Gallo,et al. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. , 1999, The Journal of biological chemistry.
[212] L. Moore,et al. A Structural Basis for Constitutive Activity in the Human CAR/RXRα Heterodimer , 2004 .
[213] A. Billin. PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. , 2008, Expert opinion on investigational drugs.
[214] Y. Okada,et al. Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. , 2010, Carcinogenesis.
[215] K. Umesono,et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[216] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[217] M. Redinbo,et al. Structural insights into the promiscuity and function of the human pregnane X receptor. , 2002, Current opinion in drug discovery & development.
[218] R. Pyzalski,et al. The Aryl Hydrocarbon Receptor Is Required for Developmental Closure of the Ductus Venosus in the Neonatal Mouse , 2005, Molecular Pharmacology.
[219] M. Klingenberg. Pigments of rat liver microsomes. , 2003, Archives of biochemistry and biophysics.
[220] J. Auwerx,et al. PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter , 1998 .
[221] Alfonso Lampen,et al. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. , 2005, Carcinogenesis.
[222] S. Amin,et al. Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines. , 2008, Toxicology.
[223] J. Peters,et al. Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. , 2008, Clinical science.
[224] A. Y. Lu,et al. CYP1A Induction and Human Risk Assessment: An Evolving Tale of in Vitro and in Vivo Studies , 2007, Drug Metabolism and Disposition.
[225] Sung-Dae Cho,et al. Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells , 2010, Cancer Chemotherapy and Pharmacology.
[226] R. T. Williams,et al. HISTORY OF THE DISCOVERY OF THE CONJUGATION MECHANISMS , 1970 .
[227] S. Amin,et al. Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. , 2010, Chemical research in toxicology.
[228] J. Lehmann,et al. An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.
[229] P. Limburg,et al. Rapid automated enzyme immunoassay of serum amyloid A. , 1994, Clinical chemistry.
[230] O. Braissant,et al. Differential Expression of Peroxisome Proliferator-Activated Receptor- , - , and - during Rat Embryonic Development , 1998 .
[231] I. Kushner,et al. Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.
[232] Y. Yano,et al. Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. , 2005, FEBS letters.
[233] T. P. Krishnakantha,et al. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate , 1975, Science.
[234] S. Ryu,et al. Serum Amyloid A Binding to Formyl Peptide Receptor-Like 1 Induces Synovial Hyperplasia and Angiogenesis1 , 2006, The Journal of Immunology.
[235] A. Mahfoudi,et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[236] S. Kliewer,et al. Use of the nuclear receptor PXR to predict drug interactions. , 2000, Toxicology.
[237] R. Flavell,et al. Nuclear Receptor CAR Represses TNFα-Induced Cell Death by Interacting with the Anti-Apoptotic GADD45B , 2010, PloS one.
[238] Barry M. Forman,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .
[239] L. Moore,et al. A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. , 2004, Molecular cell.
[240] G. Perdew,et al. Mechanistic Insights into the Events That Lead to Synergistic Induction of Interleukin 6 Transcription upon Activation of the Aryl Hydrocarbon Receptor and Inflammatory Signaling , 2010, The Journal of Biological Chemistry.
[241] N. Mitro,et al. T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR , 2007, FEBS letters.
[242] F. Guengerich,et al. Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. , 1982, Biochemistry.
[243] T. Gasiewicz,et al. Expression and activity of aryl hydrocarbon receptors in development and cancer. , 2008, Critical reviews in eukaryotic gene expression.
[244] R. Evans,et al. The Constitutive Androstane Receptor and Pregnane X Receptor Function Coordinately to Prevent Bile Acid-induced Hepatotoxicity* , 2004, Journal of Biological Chemistry.
[245] A. Peck,et al. Breaking old paradigms: Th17 cells in autoimmune arthritis. , 2009, Clinical immunology.
[246] J. Ward,et al. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. , 2008, Hepatology.
[247] J. Pascussi,et al. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. , 2008, Molecular pharmaceutics.
[248] Reddy Jk,et al. Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans , 1983 .
[249] D. Moore,et al. Differential Transactivation by Two Isoforms of the Orphan Nuclear Hormone Receptor CAR* , 1997, The Journal of Biological Chemistry.
[250] N. Sládek,et al. Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats. , 1966, Biochemical and biophysical research communications.
[251] S. Lien,et al. Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. , 2001, Biochemical and biophysical research communications.
[252] J. Caldwell. Conjugation Mechanisms of Xenobiotic Metabolism: Mammalian Aspects , 1986 .
[253] J. Lehmann,et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. , 2002, Molecular pharmacology.
[254] Ayumi Kasai,et al. Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. , 2007, Cancer letters.
[255] Bradley L Urquhart,et al. Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.
[256] C. Koike,et al. Nuclear Receptors CAR and PXR Cross Talk with FOXO1 To Regulate Genes That Encode Drug-Metabolizing and Gluconeogenic Enzymes , 2004, Molecular and Cellular Biology.
[257] S. O’Rahilly,et al. PPARγ and human metabolic disease , 2006 .
[258] A. Anderson,et al. Localization of a phenobarbital-responsive element (PBRE) in the 5'-flanking region of the rat CYP2B2 gene. , 1995, Gene.
[259] O. Hankinson. The aryl hydrocarbon receptor complex. , 1995, Annual review of pharmacology and toxicology.
[260] W. Wahli,et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. , 2001, Endocrinology.
[261] J. Gustafsson,et al. Interactions of indolo[3,2-b]carbazoles and related polycyclic aromatic hydrocarbons with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. , 1993, Molecular pharmacology.
[262] J. Preiß,et al. Adverse Health Effects in Humans Exposed to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) , 2006, Reviews on environmental health.
[263] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[264] S. Ha,et al. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. , 1993 .
[265] C. Glass,et al. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[266] Jerrold M. Olefsky,et al. PPARδ regulates glucose metabolism and insulin sensitivity , 2006 .
[267] James E Klaunig,et al. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. , 2003, Critical reviews in toxicology.
[268] Yonggong Zhai,et al. The Constitutive Androstane Receptor Is an Anti-obesity Nuclear Receptor That Improves Insulin Sensitivity* , 2009, The Journal of Biological Chemistry.
[269] Garet P Lahvis,et al. Abnormal Liver Development and Resistance to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Toxicity in Mice Carrying a Mutation in the DNA-Binding Domain of the Aryl Hydrocarbon Receptor , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[270] P. Harper,et al. Characterization of the Ah receptor and aryl hydrocarbon hydroxylase induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and benz(a)anthracene in the human A431 squamous cell carcinoma line. , 1988, Cancer research.
[271] T. Willson,et al. Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. , 2010, Journal of Medicinal Chemistry.
[272] L. Moore,et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[273] J. Schlezinger,et al. Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study , 2003, Environmental health : a global access science source.
[274] R. Maronpot,et al. The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice , 2004, Cancer Research.
[275] I. Rusyn,et al. Genomic Profiling in Nuclear Receptor-Mediated Toxicity , 2007, Toxicologic pathology.
[276] M. Krasowski,et al. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. , 2006, Current drug metabolism.
[277] C. J. Omiecinski,et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[278] T. Willson,et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes , 2007 .
[279] T. Willson,et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. , 2003, Bioorganic & medicinal chemistry letters.
[280] W. Wahli,et al. DNA Binding Properties of Peroxisome Proliferator-activated Receptor Subtypes on Various Natural Peroxisome Proliferator Response Elements , 1997, The Journal of Biological Chemistry.